KM
ACAD icon

Kalos Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Kalos Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,075
Closed -$244K – 44
2022
Q2 		$244K Sell
17,075
-1,150
-6% -$21.5K 0.33% 102
2022
Q1 		$441K Sell
18,225
-1,464
-7% -$35.4K 0.3% 75
2021
Q4 		$340K Buy
19,689
+1,114
+6% +$22.4K 0.09% 207
2021
Q3 		$321K Sell
18,575
-100
-0.5% -$1.93K 0.09% 210
2021
Q2 		$433K Hold
18,675
– – 0.18% 149
2021
Q1 		$460K Sell
18,675
-275
-1% -$12.1K 0.14% 164
2020
Q4 		$1.01M Sell
18,950
-500
-3% -$24.8K 0.43% 74
2020
Q3 		$812K Buy
19,450
+100
+0.5% +$4.32K 0.36% 84
2020
Q2 		$935K Buy
19,350
+3,600
+23% +$173K 0.39% 83
2020
Q1 		$672K Sell
15,750
-3,000
-16% -$124K 0.3% 93
2019
Q4 		$795K Hold
18,750
– – 0.29% 101
2019
Q3 		$680K Hold
18,750
– – 0.27% 105
2019
Q2 		$501K Buy
18,750
+4,829
+35% +$123K 0.23% 111
2019
Q1 		$373K Sell
13,921
-6,129
-31% -$143K 0.24% 99
2018
Q4 		$420K Buy
20,050
+800
+4% +$15.5K 0.2% 113
2018
Q3 		$392K Buy
19,250
+1,400
+8% +$22K 0.21% 110
2018
Q2 		$416K Hold
17,850
– – 0.19% 132
2018
Q1 		$416K Sell
17,850
-800
-4% -$22.1K 0.25% 94
2017
Q4 		$558K Buy
18,650
+3,500
+23% +$112K 0.26% 106
2017
Q3 		$570K Buy
+15,150
New +$493K 0.37% 83
2017
Q2 		– Sell
-10,600
Closed -$364K – 102
2017
Q1 		$364K Hold
10,600
– – 0.26% 100
2016
Q4 		$306K Buy
10,600
+1,750
+20% +$46.3K 0.25% 100
2016
Q3 		$282K Buy
8,850
+1,750
+25% +$59.3K 0.24% 117
2016
Q2 		$230K Buy
+7,100
New +$238K 0.18% 134

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kalos Management's ACAD Position: Q3 2022 in Review

Kalos Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 17,075 shares — an estimated $244K sold.

Kalos Management first reported a position in ACAD in Q2 2016 and held it in 24 quarters. The position peaked at $1.01M in Q4 2020. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Kalos Management reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Kalos Management sold 17,075 Acadia Pharmaceuticals shares in Q3 2022, an estimated $244K.
  • Kalos Management first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 24 quarters.
  • Kalos Management's Acadia Pharmaceuticals position peaked at $1.01M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Kalos Management's 13F filing for Q3 2022, filed 21 Nov 2022.